| Literature DB >> 22313792 |
Paolo Montaldo1, Lucia Tafuro, Monica Rea, Valeria Narciso, Azzurra C Iossa, Roberto Del Gado.
Abstract
OBJECTIVES: To assess the efficacy of desmopressin plus oxybutynin and compare two starting dosages of desmopressin (120 and 240 µg) in a randomized, double-blinded, placebo-controlled trial for children with monosymptomatic nocturnal enuresis (MNE) resistant to desmopressin. The predictive factors of children with MNE responsive to desmopressin and combination therapy were also evaluated. PATIENTS AND METHODS: Our sample included 206 patients aged between 6 and 13 (mean age 10.6 ± 2.9 years), 117 males. All patients were required to have MNE. The patients were randomly divided into two groups: the first group was given oral melt 120 µg and the second group 240 µg, for 2 weeks. All patients who had experienced failure of treatment with sublingually administered desmopressin alone were given either desmopressin plus 5 mg oxybutynin or desmopressin plus placebo in a randomized, double-blinded trial for 4 weeks. As predictive factors, bladder volume and wall thickness index, nocturnal polyuria and voiding latency were considered.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22313792 DOI: 10.1111/j.1464-410X.2011.10918.x
Source DB: PubMed Journal: BJU Int ISSN: 1464-4096 Impact factor: 5.588